newsfilter
← Latest News
Business Wire·

KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results

-EKTERLY® now approved in the US and UK; first and only oral on-demand therapy for acute attacks of hereditary angioedema- -Initiated US EKTERLY launch in July; received 460 patient start forms through